Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor –positive/human epidermal growth factor receptor 2–negative metastatic breast cancer in PALOMA-3

The addition of palbociclib to fulvestrant improved clinical outcomes over placebo-fulvestrant in endocrine-pretreated metastatic breast cancer (MBC) patients in PALOMA-3. Here, we examined factors predictive of long-term benefit.

Source: European Journal of Cancer - October 8, 2018 Category: Cancer & Oncology Authors: Massimo Cristofanilli, Angela DeMichele, Carla Giorgetti, Nicholas C. Turner, Dennis J. Slamon, Seock-Ah Im, Norikazu Masuda, Shailendra Verma, Sherene Loi, Marco Colleoni, Kathy Puyana Theall, Xin Huang, Yuan Liu, Cynthia Huang Bartlett Tags: Original Research Source Type: research